Krystal Biotech, Inc. (KRYS)

Krystal Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	10.93	-139.98	-69.57	-32.17	-19.09
Depreciation & Amortization	5.01	2.64	1.85	1.85	1.09
Share-Based Compensation	39.93	33.23	15.32	3.27	1.24
Other Operating Activities	-144.68	3.53	4.46	0.96	-1.93
Operating Cash Flow	-88.8	-100.57	-47.94	-26.08	-18.69
Capital Expenditures	88.2	-52.98	-68.34	-14.84	-6.4
Change in Investments	-5.56	-61.1	-158.43	3.66	1.41
Investing Cash Flow	82.64	-114.08	-226.77	-11.18	-4.99
Share Issuance / Repurchase	203.5	36	355.65	118.02	107.53
Debt Issued / Paid	0	0	-7.96	0	0
Other Financing Activities	-0.75	-0.65	-	-	-
Financing Cash Flow	202.75	35.35	347.69	118.02	107.53
Exchange Rate Effect	-0.16	-0.04	0	0	0
Net Cash Flow	196.43	-179.35	72.98	80.76	83.84
Free Cash Flow	-0.6	-153.55	-116.27	-40.93	-25.09
Free Cash Flow Margin	-1.19%	-	-	-	-
Free Cash Flow Per Share	-0.02	-6.02	-5.24	-2.18	-1.58

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).